• DOI:10.1542/peds.2013-2940
• Corpus ID: 5938129

Duration of Protection After Infant Hepatitis B Vaccination Series

@article{Middleman2014DurationOP,
  title={Duration of Protection After Infant Hepatitis B Vaccination Series},
  author={Amy B. Middleman and Carol J. Baker and Claudia A. Kozinetz and Saleem Kamili and Chi Nguyen and Dale J. Hu and Philip R Spradling},
  journal={Pediatrics},
  year={2014},
  volume={133},
  pages={e1500 - e1507}
}

• A. Middleman, C. Baker, +4 authors P. Spradling
• Published 1 June 2014
• Medicine
• Pediatrics

BACKGROUND: Little is known about duration of protection after the infant primary series of hepatitis B (HB) vaccine in settings of low HB endemicity. This study sought to determine the proportion of adolescents immunized as infants who had protective titers of antibody to hepatitis B surface antigen (anti-HBs) before and after a challenge dose of vaccine. METHODS: US-born 16- through 19-year-olds who received a recombinant HB vaccine 3-dose series initiated within 7 days of birth (group 1) or at ≥4 weeks of age (group 2) and completed by 12 months of age were enrolled. Participants had serologic testing before and 2 weeks after randomization to receive a challenge dose of 10 µg or 20 µg of Engerix-B. Baseline and postchallenge levels of anti-HBs were compared by group, challenge dosage, and demographic and behavioral characteristics. RESULTS: At baseline, 24% had protective anti-HBs levels of ≥10 IU/mL; 92% achieved protective levels after challenge dose. Although group 1 had a lower proportion of seroprotection at baseline, group and challenge dosage were not associated with postchallenge proportion of seroprotection. Being in group 2, higher test dosage, higher baseline geometric mean titer, and nonwhite race were associated with significantly higher geometric mean titer after challenge dose. CONCLUSIONS: More than 90% of study participants immunized against HB as infants exhibited a seroprotective response to a challenge dose of vaccine. Duration of protection from the primary infant HB vaccine series extended through the adolescent years in the setting of low HB endemicity.